For years, scientists have hoped to harness the immune system to attack cancer using a group of drugs known as CD40 agonist ...

Several oncology companies announced key trial milestones this week across the landscape of both blood cancers and solid ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

The NHS is to trial “robo minders” to keep an eye on dementia patients in their own homes. The technology will allow hospital ...

Synthetic generation replicates key clinical patterns from real-world data, enabling valid analyses with fewer patients.

The upcoming Clinical Trials in Rare Diseases conference will cover the most concerning challenges in rare disease research.

Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical ...